Back

Effect of SGLT2 inhibitors in sustained ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators for primary prevention

11 May 2024 (11:00 - 11:45)
Organised by: Logo
Congress Presentation Part of: Arrhythmias & device Implantable Cardioverter-Defibrillator (ICD) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Mr Julien Lopes

Hospital de Santa Marta, Lisbon (Portugal)

6 More presentations in this session

Presentation thumbnail
Transvenous lead extraction: application of the Tandem approach in patients with heart failure
Professor M. Gallagher (London, GB)
Abstract Slides Video
Presentation thumbnail
Long term prognosis of idiopathic ventricular arrhythmias: an eighteen-year experience from a tertiary center
Doctor C. Oliveira (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Unmasking the hidden threat: non-sustained ventricular tachycardia in pacemaker patients with HFpEF and its prognostic significance on mortality and heart failure events
Miss E. Santos (Vila Nova de Gaia, PT)
Abstract Slides Video
Presentation thumbnail
Implantable cardioverter defibrillators in heart failure with reduced ejection fraction: evaluating efficacy in the era of contemporary pharmacotherapy
Doctor I. Ferreira Neves (Lisboa, PT)
Abstract Slides Video
Presentation thumbnail
Machine learning-based mortality prediction in patients undergoing CRT implantation using the SEMMELWEIS-CRT score: validation in the European CRT survey I database
Doctor M. Tokodi (Budapest, HU)
Abstract Slides Video

Access the full session

Session thumbnail
Arrhythmias & device

The Event

Event poster

Heart Failure 2024

11 May 2024 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Impact of SLGT2 inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac defibrillator
thumbnail
Congress Presentation
Implantable cardioverter defibrillators in heart failure with reduced ejection fraction: evaluating efficacy in the era of contemporary pharmacotherapy
thumbnail
Congress Presentation
Impact of SLGT2 inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac device

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources